EIF2AK3 and cancer: In breast cancer, the expression of PERK (EIF2AK3) was down-regulated, but its activity was shown to be constitutionally elevated in drug-resistant cells, and it was found that PERK could be a potential target for drug-resistant cancer therapy [58].